Zucara Therapeutics Inc.
Richard Liggins has extensive work experience in the biopharmaceutical industry. Richard is currently serving as the Co Founder & Chief Scientific Officer at Zucara Therapeutics Inc. since January 2015. Prior to this, they held various roles at the Centre for Drug Research and Development, including Senior Director, Head of Analytical & Preformulation, and Deputy Head, Analytical & Preformulation, from 2006 to 2019. Richard also co-founded Sitka Biopharma in December 2013 and worked as a collaborator until 2019. In addition, Richard served as an Adjunct Professor of Pharmaceutical Sciences at The University of British Columbia from 2002 to 2018. Richard started their career as a Formulation Scientist at Angiotech in 1998, where they worked until 2006.
Richard Liggins completed their education at The University of British Columbia. From 1988 to 1993, they pursued a Bachelor of Science (BSc) degree in Pharmaceutical Sciences. Following this, they continued their academic journey at the same institution and obtained a PhD in Pharmaceutics & Drug Delivery from 1993 to 1998.
This person is not in any teams
This person is not in any offices
Zucara Therapeutics Inc.
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically blocksomatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.